Stockscreener 앱 받기
306.07
0.79%
-2.65
전일 마감가:
$308.72
열려 있는:
$305.76
하루 거래량:
27,695
Relative Volume:
0.06
시가총액:
$13.81B
수익:
$2.99B
순이익/손실:
$1.21B
주가수익비율:
12.21
EPS:
25.06
순현금흐름:
$1.13B
1주 성능:
+0.30%
1개월 성능:
+4.37%
6개월 성능:
-17.87%
1년 성능:
+10.77%
1일 변동 폭
$302.79
$307.15
1주일 범위
$300.51
$311.99
52주 변동 폭
$264.33
$417.81
유나이티드 테라퓨틱스 Stock (UTHR) Company Profile
명칭
United Therapeutics Corp
전화
(301) 608-9292
주소
1000 SPRING ST, SILVER SPRING, MD
UTHR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
UTHR
United Therapeutics Corp
|
306.18 | 13.71B | 2.99B | 1.21B | 1.13B | 25.06 |
|
HLN
Haleon Plc Adr
|
11.14 | 48.05B | 14.35B | 1.85B | 0 | 0.4023 |
|
ZTS
Zoetis Inc
|
160.76 | 71.39B | 9.29B | 2.52B | 2.28B | 5.57 |
|
RDHL
Redhill Biopharma Ltd Adr
|
1.80 | 3.20M | 35.75M | 11.57M | -26.25M | -3.8069 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.49 | 43.73B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.71 | 19.35B | 16.54B | -1.64B | 749.00M | -1.45 |
유나이티드 테라퓨틱스 Stock (UTHR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-25 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2025-04-21 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2024-07-11 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-12 | 업그레이드 | Goldman | Sell → Neutral |
| 2024-02-05 | 개시 | Leerink Partners | Outperform |
| 2023-12-08 | 개시 | Wells Fargo | Overweight |
| 2022-12-06 | 개시 | UBS | Buy |
| 2022-12-05 | 개시 | Goldman | Sell |
| 2022-10-11 | 개시 | Morgan Stanley | Overweight |
| 2022-09-20 | 재확인 | BofA Securities | Underperform |
| 2022-09-19 | 재개 | Wedbush | Outperform |
| 2022-02-11 | 개시 | BTIG Research | Neutral |
| 2021-07-14 | 업그레이드 | Argus | Hold → Buy |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-02-01 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-09-14 | 재개 | JP Morgan | Overweight |
| 2020-06-25 | 재확인 | H.C. Wainwright | Neutral |
| 2020-03-10 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-02-27 | 업그레이드 | Cowen | Market Perform → Outperform |
| 2020-01-31 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-12-03 | 개시 | BofA/Merrill | Underperform |
| 2019-08-01 | 업그레이드 | Jefferies | Underperform → Hold |
| 2019-08-01 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2019-07-01 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2019-05-17 | 업그레이드 | UBS | Sell → Neutral |
| 2019-05-09 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2018-10-12 | 업그레이드 | Standpoint Research | Hold → Buy |
| 2018-08-08 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2018-04-03 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2018-02-22 | 재확인 | Barclays | Underweight |
| 2018-01-18 | 재개 | Credit Suisse | Underperform |
| 2017-12-27 | 재확인 | Wedbush | Outperform |
| 2017-04-27 | 재확인 | Wedbush | Outperform |
| 2017-03-30 | 개시 | UBS | Sell |
| 2017-03-16 | 개시 | Credit Suisse | Underperform |
모두보기
유나이티드 테라퓨틱스 주식(UTHR)의 최신 뉴스
HHS layoffs create ‘clear opportunity’ for local health, life sciences companies to add talent - The Business Journals
Liquidia Says UTC Can’t Stop Its New Lung Drug From Launching - Bloomberg Law News
Stewartville pig-to-human transplant facility to be complete in 2026 - Post Bulletin
Interesting UTHR Put And Call Options For July 18th - Nasdaq
Q1 Therapeutics Earnings: United Therapeutics (NASDAQ:UTHR) Impresses - Yahoo Finance
UTHR Q1 Earnings Call: Double-Digit Growth Continues, Pipeline Expansion Remains Central - Yahoo Finance
UTC Again Seeks To Stave Off Lung Drug Competitor In IP Suit - Law360
Liquidia Faces Patent Litigation Filed by United Therapeutics - marketscreener.com
Liquidia (LQDA) Faces Patent Infringement Lawsuit from United Th - GuruFocus
Liquidia Says New Litigation Filed Against Co In U.S. - marketscreener.com
Liquidia Corporation Provides Update on Litigation Filed by United Therapeutics - Yahoo Finance
Is United Therapeutics (UTHR) the Best Stock to Buy According to Jim Simons’ Renaissance Technologies? - Insider Monkey
Liquidia Corp (LQDA) Q1 2025 Earnings Call Highlights: Strategic Advances and Legal Wins Propel ... - Yahoo Finance
3 Big Reasons to Love United Therapeutics (UTHR) - Yahoo Finance
MANNKIND CORP SEC 10-Q Report - TradingView
Liquidia Corporation Reports First Quarter 2025 Financial Results and Provides Corporate Update - Yahoo Finance
TD Cowen maintains United Therapeutics stock Buy rating By Investing.com - Investing.com Nigeria
TD Cowen maintains United Therapeutics stock Buy rating - Investing.com
3 Market-Beating Stocks with Solid Fundamentals - Yahoo Finance
United Therapeutics (UTHR) Target Price Lowered by Argus, Retains Buy Rating | UTHR Stock News - GuruFocus
Liquidia Fends Off Indication Challenge In UTC Tyvaso Fight - Law360
United Therapeutics (UTHR) Receives Reiterated "Buy" Rating from HC Wainwright | UTHR Stock News - GuruFocus
Liquidia Corporation: A Strong Buy On High Likelihood Of FDA Approval This Month - Seeking Alpha
District Court Dismisses Dispute Filed by United Therapeutics Against Liquidia - GlobeNewswire Inc.
US judge dismisses United Therapeutics' counterclaims over Liquidia's 'Yutrepia' - MLex
United Therapeutics (UTHR) Gets a Hold from Wells Fargo - The Globe and Mail
Legal Victory: Liquidia Clears Major Hurdle for YUTREPIA Dual-Indication Approval This Month - Stock Titan
BofA raises United Therapeutics stock target to $321 - Investing.com Australia
United Therapeutics (UTHR): Morgan Stanley Raises Price Target | - GuruFocus
BofA raises United Therapeutics stock target to $321 By Investing.com - Investing.com Canada
United Therapeutics (UTHR) Analyst Update: JP Morgan Maintains R - GuruFocus
United Therapeutics (UTHR) Analyst Update: JP Morgan Maintains Rating | UTHR Stock News - GuruFocus
United Therapeutics (UTHR): Morgan Stanley Raises Price Target | UTHR Stock News - GuruFocus
Decoding United Therapeutics Corp (UTHR): A Strategic SWOT Insig - GuruFocus
United Therapeutics Corporation (NASDAQ:UTHR) Q1 2025 Earnings Call Transcript - Insider Monkey
Avepoint, Meta, United Therapeutics - TradingView
United Therapeutics: Q1 Earnings Snapshot - New Haven Register
United Therapeutics Corp (UTHR) Q1 2025 Earnings Call Highlights: Record Revenue and Strategic ... - Yahoo Finance
United Therapeutics Reports Strong Q1 2025 Growth - TipRanks
United Therapeutics Corp. Reports Record Revenue Growth - TipRanks
Earnings call transcript: United Therapeutics Q1 2025 beats expectations - Investing.com
United Therapeutics Corp Surpasses Q1 2025 Estimates with $7.18 EPS and $794.4 Million Revenue - GuruFocus
United Therapeutics (UTHR) Surpasses Q1 Earnings Expectations - GuruFocus
United Therapeutics beats Q1 estimates, shares edge higher - Investing.com
United Therapeutics Q1 Earnings, Revenue Rise - marketscreener.com
United Therapeutics Q1 2025 slides: revenue jumps 17%, organ transplant milestone nears - Investing.com
United Therapeutics Corporation Reports First Quarter 2025 Financial Results - TradingView
UNITED THERAPEUTICS Corp SEC 10-Q Report - TradingView
유나이티드 테라퓨틱스 (UTHR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
유나이티드 테라퓨틱스 주식 (UTHR) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| MAHON PAUL A | EVP & GENERAL COUNSEL |
May 15 '25 |
Sale |
295.10 |
11,000 |
3,246,150 |
36,781 |
0.11%
0.27%
자본화:
|
볼륨(24시간):